Sodium-glucose cotransporter-2 (SGLT2) inhibitors have also been shown to be effective for weight loss and reduced hepatic fat content and may thus be beneficial in NASH [117]. Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.